Development of recombinant adeno-associated virus and adenovirus cocktail system for efficient hTERTC27 polypeptide-mediated cancer gene therapy

Cancer Gene Therapy

Volumn 15, Issue 11, 2008, Pages 723-732

  Gao, Y ^a,b   Ng, S S M ^a   Chau, D H W ^a,c,d   Yao, H ^a   Yang, C ^a   Man, K ^b   Huang, P T ^e   Huang, C ^e   Huang, J J ^e   Kung, H F ^c,d   Lin, M C ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c SUN YAT SEN UNIVERSITY   (China)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

Author keywords

Adeno associated virus; Adenovirus; Glioblastoma; hTERTC27

Indexed keywords

LUCIFERASE; RECOMBINANT ADENO ASSOCIATED VIRUS ENHANCED GREEN FLUORESCENT PROTEIN; RECOMBINANT ADENO ASSOCIATED VIRUS TELOMERASE REVERSE TRANSCRIPTASE C27; RECOMBINANT ADENOVIRUS TELOMERASE REVERSE TRANSCRIPTASE C27; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RECOMBINANT ADENOVIRUS; TUMOR REGRESSION; TUMOR VOLUME; VIRUS RECOMBINANT; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; DEPENDOVIRUS; DNA PRIMERS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; LUCIFERASES; MICE; MICE, NUDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TELOMERASE; TRANSDUCTION, GENETIC;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA; MUS MUSCULUS;

EID: 53549088873     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.33     Document Type: Article

References (31)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
2. Lawler SE, Peruzzi PP, Chiocca EA. Genetic strategies for brain tumor therapy. Cancer Gene Ther 2006; 13: 225-233.
3. Daly TM. Overview of adeno-associated viral vectors. Methods Mol Biol 2004; 246: 157-165.
4. Flotte TR, Afione SA, Zeitlin PL. Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol 1994; 11: 517-521.
5. Kearns WG, Afione SA, Fulmer SB, Pang MC, Erikson D, Egan M et al. Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line. Gene Therapy 1996; 3: 748-755.
6. Ponnazhagan S, Erikson D, Kearns WG, Zhou SZ, Nahreini P, Qang XS et al. Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells. Hum Gene Ther 1997; 8: 275-284.
7. Rutledge EA, Russell DW. Adeno-associated virus vector integration junctions. J Virol 1997; 71: 8429-8436.
8. Ma HI, Lin SZ, Chiang YH, Li J, Chen SL, Tsao YP et al. Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector. Gene Therapy 2002; 9: 2-11.
9. Okada H, Miyamura K, Itoh T, Hagiwara M, Wakabayashi T, Mizuno M et al. Gene therapy against an experimental glioma using adeno-associated virus vectors. Gene Therapy 1996; 3: 957-964.
10. Qiao C, Li J, Skold A, Zhang X, Xiao X. Feasibility of generating adeno-associated virus packaging cell lines containing inducible adenovirus helper genes. J Virol 2002; 76: 1904-1913.
11. Huang JJ, Lin MC, Bai YX, Jing DD, Wong BC, Han SW et al. Ectopic expression of a COOH-terminal fragment of the human telomerase reverse transcriptase leads to telomere dysfunction and reduction of growth and tumorigenicity in HeLa cells. Cancer Res 2002; 62: 3226-3332.
12. 2-induced senescence without affecting telomerase enzymatic activity. Biochem Biophys Res Commun 2003; 301: 627-632.
13. Ng SS, Gao Y, Chau HW, Li HY, Lai LH, Huang PT et al. A novel glioblastoma cancer gene therapy using AAV-mediated long-term expression of human TERT C-terminal polypeptide. Cancer Gene Ther 2007; 99: 936-941.
14. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70: 3227-3234.
15. Fisher KJ, Gao GP, Weitzman MD, DeMatteo R, Burda JF, Wilson JM. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996; 70: 520-532.
16. Chen Y, Luk KDK, Cheung KM, Lu WW, An XM, Ng SS. Combination of adeno-associated virus and adenovirus vectors expressing bone morphogenetic protein-2 produces enhanced osteogenic activity in immunocompetent rats. Biochem Biophys Res Commun 2004; 317: 675-681.
17. Chen Y, Luk KDK, Cheung KM, Xu R, Lin MC, Lu WW et al. Gene therapy for bone formation using adeno-associated viral bone morphogenetic protein-2 vectors. Gene Therapy 2003; 10: 1345-1353.
18. Tu SP, Cui JT, Liston P, Huajiang X, Xu R, Lin MC et al. Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology 2005; 128: 361-375.
19. Yakobson B, Koch T, Winocour E. Replication of adeno-associated virus in synchronized cells without the addition of a helper virus. J Virol 1987; 61: 972-981.
20. Yakobson B, Hrynko TA, Peak MJ, Winocour E. Replication of adeno-associated virus in cells irradiated with UV light at 254 nm. J Virol 1989; 63: 1023-1030.
21. Bromberg JS, Debruyne LA, Qin L. Interactions between the immune system and gene therapy vectors: bidirectional regulation of response and expression. Adv Immunol 1998; 69: 353-409.
22. Hackett NR, Kaminsky SM, Sondhi D, Crystal RG. Antivector and antitransgene host responses in gene therapy. Curr Opin Mol Ther 2000; 2: 376-382.
23. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997; 8: 37-44.
24. Liu Q, Muruve DA. Molecular basis of the inflammatory response to adenovirus vectors. Gene Therapy 2003; 10: 935-940.
25. Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 1997; 3: 306-312.
26. Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999; 5: 56-63.
27. Croy BA, Linder KE, Yager JA. Primer for non-immunologists on immune-deficient mice and their applications in research. Comp Med 2001; 51: 300-313.
28. Parney IF, Farr-Jones MA, Chang LJ, Petruk KC. Human glioma immunobiology in vitro: implications for immunogene therapy. Neurosurgery 2000; 46: 1169-1177.
29. Weller M, Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Brain Res Rev 1995; 21: 128-151.
30. Miller DW. Immunobiology of the blood-brain barrier. J Neurovirol 1999; 5: 570-578.
31. Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 1991; 28: 254-260.